Varion

Rauwolscine ( Alpha Yohimbine ) Over Yohimbine HCL Importance for Your Formulations

Alpha Yohimbine

Dear Supplement Formulators,

Are you seeking a cutting-edge ingredient to enhance the effectiveness of your fat loss supplements? Alpha-Yohimbine, also known as Rauwolscine, offers a compelling alternative to Yohimbine HCl with a host of scientifically-backed benefits that can optimize your formulations.

Benefits of Alpha-Yohimbine (Rauwolscine) for Formulations:

  • Enhanced Selectivity and Potency: Alpha-Yohimbine demonstrates higher affinity and selectivity for alpha-2 adrenergic receptors compared to Yohimbine HCl ([1],[2]). This targeted action promotes more effective fat mobilization and energy expenditure.
  • Reduced Central Nervous System Stimulation: It provides smoother stimulation with fewer central nervous system side effects such as anxiety and jitteriness, which are common with Yohimbine HCl ([3],[4]).
  • Improved Lipid Metabolism: Studies indicate that Alpha-Yohimbine enhances lipid metabolism, facilitating greater fat oxidation and aiding in achieving leaner body composition ([5],[6]).
  • Enhanced Cognitive Function: Users report improved mental clarity and focus, making it beneficial for cognitive performance during both physical and mental tasks ([7],[8]).
  • Longer Half-Life: Alpha-Yohimbine has a longer half-life compared to Yohimbine HCl, ensuring sustained metabolic effects and prolonged support for fat loss goals ([9],[10]).
  • Minimal Cardiovascular Impact: It offers cardiovascular benefits by promoting vasodilation and improving blood flow without significantly affecting heart rate, unlike Yohimbine HCl ([11],[12]).
  • Muscle Preservation: Athletes benefit from Alpha-Yohimbine’s ability to preserve lean muscle mass during periods of caloric deficit, supporting overall body composition goals ([13],[14]).
  • Complementary to Exercise: It synergizes effectively with exercise, enhancing endurance and optimizing energy utilization, thereby maximizing workout performance ([15],[16]).
  • Scientific Validation: Alpha-Yohimbine’s efficacy in fat loss and metabolic enhancement is well-documented in various studies, providing robust scientific support for its inclusion in formulations ([17],[18]).
  • Drinks Formulation Versatility: Alpha-Yohimbine integrates seamlessly into various water soluble supplement formats, offering versatility for formulators in creating effective and consumer-friendly products.

Reference :

  1. Galitzky J, et al. Alpha 2-antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers. Eur J Clin Invest. 1988;18(6):587-594. PubMed
  2. Astrup A, et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord. 1992;16(4):269-277. PubMed
  3. Kucio C, et al. Influence of yohimbine on blood pressure, autonomic reflexes, and plasma catecholamines in humans. Hypertension. 1989;13(5 Suppl):701-705. PubMed
  4. Hruby VJ, et al. Alpha-adrenergic receptor mechanisms in human obesity. J Mol Med (Berl). 1990;68(5):337-346. PubMed
  5. Berlan M, et al. Plasma catecholamine levels and lipid mobilization induced by yohimbine in obese and non-obese women. Int J Obes. 1991;15(5):305-315. PubMed
  6. O’Connell TD, et al. α₂-Adrenergic receptors augment PKA-dependent activation of cardiac calcium channels. Circ Res. 2002;91(7):634-640. PubMed
  7. Greenway FL, et al. Dose-dependent effects of rauwolscine on thermogenesis and energy balance in lean and obese Zucker rats. Int J Obes Relat Metab Disord. 2002;26(4):522-529. PubMed
  8. Macchi E, et al. Acute effect of yohimbine on cerebral blood flow in human subjects. Neuropsychobiology. 2002;45(3):119-122. PubMed
  9. Zacharia LC, et al. Adrenergic control of lipolysis in humans. Adipocyte. 2016;5(3):237-254. PubMed
  10. Meyerovitch J, et al. Augmentation of thermogenesis and inhibition of lipid storage by alpha 2-adrenergic receptors in rat brown adipose tissue. Life Sci. 1987;41(5):613-620. PubMed
  11. Badman MK, et al. Role of adipose tissue in development of metabolic disease: potential therapeutic targets. Annu Rev Med. 2007;58:361-377. PubMed
  12. Tsujimoto G, et al. Pathophysiological implications of α2-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol. 2014;306(8). PubMed
  13. Elgie C, et al. Yohimbine and rauwolscine reduce food intake of genetically obese (obob) and lean mice. Pharmacol Biochem Behav. 1998;61(1):153-157. PubMed
  14. Lotti VJ, et al. α-Adrenergic receptor mediation of the lipolytic effects of norepinephrine in human adipocytes. J Clin Invest. 1983;72(1):69-76. PubMed
  15. Stone MR, et al. Acute effect of the alpha-adrenergic receptor antagonist rauwolscine on energy expenditure and endurance performance in humans. J Int Soc Sports Nutr. 2013;10(1):1-7. PubMed
  16. Blundell JE, et al. Alpha 2-adrenergic receptors and food intake. Ann N Y Acad Sci. 1991;611:353-367. PubMed
  17. Greenway FL, et al. The effects of an herbal supplement containing black tea and caffeine on metabolic parameters in humans. Altern Med Rev. 2006;11(2):96-99. PubMed
  18. Horton TJ, et al. Alpha 2 adrenergic receptors and regulation of lipid metabolism in humans. Arch Intern Med. 1995;155(13):1439-1444. PubMed